PT  - JOURNAL ARTICLE
AU  - TAMBURO, MARIA
AU  - BUFFETTINO, EMANUELE
AU  - PEPE, PIETRO
AU  - MARLETTA, GIULIA
AU  - PEPE, LUDOVICA
AU  - COSENTINO, SEBASTIANO
AU  - IPPOLITO, MASSIMO
AU  - PENNISI, MICHELE
AU  - MARLETTA, FRANCESCO
TI  - Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence
AID  - 10.21873/anticanres.17027
DP  - 2024 May 01
TA  - Anticancer Research
PG  - 2205--2210
VI  - 44
IP  - 5
4099  - http://ar.iiarjournals.org/content/44/5/2205.short
4100  - http://ar.iiarjournals.org/content/44/5/2205.full
SO  - Anticancer Res2024 May 01; 44
AB  - Background/Aim: To evaluate the clinical outcome in men with recurrent prostate cancer (PCa) treated by salvage radiotherapy (sRT) prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT)-guided. Patients and Methods: From January 2021 to January 2023, 33 patients who previously underwent definitive/systemic therapy were submitted to sRT PSMA PET/CT-guided for PCa recurrence: 16 (48.5%) on the prostate bed (PB), 12 (36.4%) on the lymph node (LN) and five (15.1%) on the bone. The median PSA value was 3.3 ng/ml (range=0.3-15.5 ng/ml): 0.2-0.5 ng/ml (18.2% cases), 0.51-1 ng/ml (39.4% cases) and >1 ng/ml (42.4% cases). Median 18F PSMA PET/CT standardized uptake value (SUVmax) was evaluated on PB, vs. LN vs. bones PCa recurrences and was equal to 12.5 vs. 19.0 vs. 30.1, respectively. Results: Overall, at a median follow up of 12 months, 23/33 patients (69.7%) had local control without distant progression (PSA and SUVmax evaluation): 14/16 (87.5%) vs. 7/12 (58.3%) vs. 2/5 (40%) underwent sRT on the PB vs. LN vs. bone metastases, respectively. Conclusion: PSMA PET/CT allows to perform sRT early in men with PCa recurrence and low PSA values obtaining a complete clinical response in approximately 70% of the cases one year from treatment.